Influenza

Safety and Efficacy: IV Zanamivir vs Oral Oseltamivir in Severe Influenza

By

Cindy Lampner

Intravenous zanamivir is as safe and effective as oral oseltamivir when used in patients with severe influenza.

High-Dose Influenza Quadrivalent Approved for Patients 65 Years and Older

By

Brian Park, PharmD

The FDA has approved the supplemental Biologics License Application (sBLA) for Fluzone High-Dose Quadrivalent for active immunization for the prevention of influenza disease in patients aged ≥65 years.

Single Dose Oral Baloxavir Well-Tolerated in Pediatric Influenza

By

Pulmonology Advisor Contributing Writer

Baloxavir marboxil was well-tolerated in a pediatric population and rapidly reduced viral titers.

Baloxavir Marboxil Approved in Patients at High Risk for Flu-Related Complications

By

Steve Duffy

The FDA has approved a supplemental NDA for Xofluza for the treatment of acute, uncomplicated influenza in patients aged 12 years and older.

Hospitalization Risk With Influenza Higher in Type 2 Diabetes

Although the risk for hospitalization with influenza was higher in patients with type 2 diabetes, mortality rates were lower.

CDC: Seasonal Influenza Viruses Circulating Widely in Southern Hemisphere

Influenza A(H3) is predominating in many regions in Southern Hemisphere while influenza activity remains low in the United States.

Influenza Vaccine Modestly Effective in Preventing Hospitalizations in COPD

By

Virginia A. Schad, PharmD, RPh

Influenza vaccination can be modestly effective in reducing laboratory-confirmed influenza-associated hospitalizations in people with chronic obstructive pulmonary disease.

Survey: Many US Adults Not Planning to Receive Influenza Vaccine

Vaccine knowledge and anticipated rates of vaccination are even lower for pneumococcal disease.

Probiotics May Reduce Costs for Flu-Like Respiratory Tract Infections

Cost savings could include reductions in respiratory tract infections, antibiotic prescriptions, and sick days.